A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer’s Disease

References

• Acharya, A., Blackwell, M., and Sen, M. (2016), “Explaining Causal Findings Without Bias: Detecting and Assessing Direct Effects,” American Political Science Review, 110, 512–529. DOI: 10.1017/S0003055416000216.
   Web of Science ®Google Scholar
• Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol-Ripoll, G., Gámez, J. E., and Anaya, F. (2020), “A Randomized, Controlled Clinical Trial of Plasma Exchange with Albumin Replacement for Alzheimer’s Disease: Primary Results of the AMBAR Study,” Alzheimer’s & Dementia, 16, 1412–1425.
   PubMed Web of Science ®Google Scholar
• Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.-J., Rogers, S., and Friedhoff, L. (1999), “The Effects of Donepezil in Alzheimer’s Disease—Results from a Multinational Trial 1,” Dementia and Geriatric Cognitive Disorders, 10, 237–244. DOI: 10.1159/000017126.
   PubMed Web of Science ®Google Scholar
• Buuren, S. V., and Groothuis-Oudshoorn, K. (2010), “mice: Multivariate Imputation by Chained Equations in R,” Journal of Statistical Software, 45, 1–68.
   Web of Science ®Google Scholar
• Canty, A., and Ripley, B. (2019), “boot: Bootstrap R (S-Plus) Functions,” R Package Version 1. 3–22, 1.
   Google Scholar
• Cedarbaum, J. M., Jaros, M., Hernandez, C., Coley, N., Andrieu, S., Grundman, M., Vellas, B., and Alzheimer’s Disease Neuroimaging Initiative. (2013), “Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials,” Alzheimer’s & Dementia, 9, S45–S55.
   PubMed Web of Science ®Google Scholar
• Conrado, D. J., Willis, B., Sinha, V., Nicholas, T., Burton, J., Stone, J., Chen, D., Coello, N., Wang, W., and Kern, V. D. (2018), “Towards FDA and EMA Endorsement* of a Clinical Trial Simulation Tool for Amnestic Mild Cognitive Impairment,” Journal of Pharmacokinetics and Pharmacodynamics, 45, S17.
   Web of Science ®Google Scholar
• Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., and Shiovitz, T. (2015), “Targeting Prodromal Alzheimer Disease with Avagacestat: A Randomized Clinical Trial,” JAMA Neurology, 72, 1324–1333. DOI: 10.1001/jamaneurol.2015.0607.
   PubMed Web of Science ®Google Scholar
• Cummings, J., Lee, G., Ritter, A., Sabbagh, M., and Zhong, K. (2019), “Alzheimer’s Disease Drug Development Pipeline: 2019,” Alzheimer’s & Dementia: Translational Research & Clinical Intervention, 5, 272–293. DOI: 10.1016/j.trci.2019.05.008.
   PubMedGoogle Scholar
• Cummings, J. L. (2009), “Defining and Labeling Disease-Modifying Treatments for Alzheimer’s Disease,” Alzheimer’s & Dementia, 5, 406–418.
   PubMed Web of Science ®Google Scholar
• Cunningham, S. (2021), Causal Inference, New Haven, CT: Yale University Press.
   Google Scholar
• Davison, A. C., and Hinkley, D. V. (1997), Bootstrap Methods and Their Application, New York: Cambridge University Press.
   Google Scholar
• Donohue, M. C., Model, F., Delmar, P., Volye, N., Liu-Seifert, H., Rafii, M. S., Aisen, P. S., and Alzheimer’s Disease Neuroimaging Initiative (2020), “Initiation of Symptomatic Medication in Alzheimer’s Disease Clinical Trials: Hypothetical Versus Treatment Policy Approach,” Alzheimer’s & Dementia, 16, 797–803. DOI: 10.1002/alz.12058.
   PubMed Web of Science ®Google Scholar
• Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., and Galasko, D. (2010), “Revising the Definition of Alzheimer’s Disease: A New Lexicon,” The Lancet Neurology, 9, 1118–1127. DOI: 10.1016/S1474-4422(10)70223-4.
   PubMed Web of Science ®Google Scholar
• Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., and Bateman, R. (2014), “Advancing Research Diagnostic Criteria for Alzheimer’s Disease: The IWG-2 Criteria,” The Lancet Neurology, 13, 614–629. DOI: 10.1016/S1474-4422(14)70090-0.
   PubMed Web of Science ®Google Scholar
• Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., and Boada, M. (2019), “Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease,” The New England Journal of Medicine, 380, 1408–1420. DOI: 10.1056/NEJMoa1812840.
   PubMed Web of Science ®Google Scholar
• Elwert, F. (2013), “Graphical Causal Models,” in Handbook of Causal Analysis for Social Research, eds. S. L. Morgan, pp. 245–273, Dordrecht: Springer.
   Google Scholar
• EMA (2018), “Guideline on the Clinical Investigation of Medicines for the Treatment of Alzheimer’s Disease.”
   Google Scholar
• FDA (2020), “Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document,” available at https://www.fda.gov/media/143502/download.
   Google Scholar
• Goetgeluk, S., Vansteelandt, S., and Goetghebeur, E. (2008), “Estimation of Controlled Direct Effects,” Journal of the Royal Statistical Society, Series B, 70, 1049–1066. DOI: 10.1111/j.1467-9868.2008.00673.x.
   Google Scholar
• Hernán, M. A., and Robins, J. M. (2020), Causal Inference: What If, Boca Raton, FL: Chapman & Hill/CRC.
   Google Scholar
• Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., and Alzheimer’s Disease Neuroimaging Initiative. (2012), “Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials,” PloS One, 7, e47739. DOI: 10.1371/journal.pone.0047739.
   PubMed Web of Science ®Google Scholar
• Howard, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., and Bentham, P. (2020), “Minocycline at 2 Ddifferent Dosages vs Placebo for Patients with Mild Alzheimer Disease: A Randomized Clinical Trial,” JAMA Neurology, 77, 164–174. DOI: 10.1001/jamaneurol.2019.3762.
   PubMed Web of Science ®Google Scholar
• ICH (2018), “ICH E9(R1) Step 2 Training Material.” odule 2.3—Estimands.
   Google Scholar
• ICH (2019), “Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials E9(R1).”
   Google Scholar
• Komarova, N. L., and Thalhauser, C. J. (2011), “High Degree of Heterogeneity in Alzheimer’s Disease Progression Patterns,” PLoS Computational Biology, 7, e1002251. DOI: 10.1371/journal.pcbi.1002251.
   PubMed Web of Science ®Google Scholar
• Lanctôt, K. L., Herrmann, N., Yau, K. K., Khan, L. R., Liu, B. A., LouLou, M. M., and Einarson, T. R. (2003), “Efficacy and Safety of Cholinesterase Inhibitors in Alzheimer’s Disease: A Meta-Analysis,” CMAJ, 169, 557–564.
   PubMed Web of Science ®Google Scholar
• Last, J. (2000), A Dictionary of Epidemiology (4th ed.), New York: Oxford University Press.
   Google Scholar
• Lepage, B., Dedieu, D., Savy, N., and Lang, T. (2016), “Estimating Controlled Direct Effects in the Presence of Intermediate Confounding of the Mediator-Outcome Relationship: Comparison of Five Different Methods,” Statistical Methods in Medical Research, 25, 553–570. DOI: 10.1177/0962280212461194.
   PubMed Web of Science ®Google Scholar
• Loh, W. W., Moerkerke, B., Loeys, T., Poppe, L., Crombez, G., and Vansteelandt, S. (2019), “Estimation of Controlled Direct Effects in Longitudinal Mediation Analyses with Latent Variables in Randomized Studies,” Multivariate Behavioral Research, 55, 763–785. DOI: 10.1080/00273171.2019.1681251.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt, C., Molenberghs, G., Lipkovich, I., and Ratitch, B. (2019), Estimands, Estimators and Sensitivity Analysis in Clinical Trials, Boca Raton, FL: CRC Press.
   Google Scholar
• Matthew Blackwell, A. A., Sen, M., Kuriwaki, S., and Brown, J. (2019), “DirectEffects: Estimating Controlled Direct Effects for Explaining,” available at https://cran.r-project.org/web/packages/DirectEffects/index.html
   Google Scholar
• Mehta, D., Jackson, R., Paul, G., Shi, J., and Sabbagh, M. (2017), “Why do Trials for Alzheimer’s Disease Drugs Keep Failing? A Discontinued Drug Perspective for 2010–2015,” Expert Opinion on Investigational Drugs, 26, 735–739. DOI: 10.1080/13543784.2017.1323868.
   PubMed Web of Science ®Google Scholar
• Montgomery, W., Goren, A., Kahle-Wrobleski, K., Nakamura, T., and Ueda, K. (2018), “Alzheimer’s Disease Severity and its Association with Patient and Caregiver Quality of Life in Japan: Results of a Community-Based Survey,” BMC Geriatrics, 18, 141. DOI: 10.1186/s12877-018-0831-2.
   PubMed Web of Science ®Google Scholar
• Morris, T. P., White, I. R., and Crowther, M. J. (2019), “Using Simulation Studies to Evaluate Statistical Methods,” Statistics in Medicine, 38, 2074–2102. DOI: 10.1002/sim.8086.
   PubMed Web of Science ®Google Scholar
• Morris, T. P., White, I. R., and Royston, P. (2014), “Tuning Multiple Imputation by Predictive Mean Matching and Local Residual Draws,” BMC Medical Research Methodology, 14, 1–13. DOI: 10.1186/1471-2288-14-75.
   PubMed Web of Science ®Google Scholar
• Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar. (2017), “A Phase III Randomized Trial of Gantenerumab in Prodromal Alzheimer’s Disease,” Alzheimer’s Research & Therapy, 9, 95.
   PubMed Web of Science ®Google Scholar
• Pearl, J. (1995), “Causal Diagrams for Empirical Research,” Biometrika, 82, 669–688. DOI: 10.1093/biomet/82.4.669.
   Web of Science ®Google Scholar
• Pearl, J. (2013), “Direct and Indirect Effects,” arXiv Preprint arXiv:1301.2300
   Google Scholar
• Pearl, J. (2014), “Interpretation and Identification of Causal Mediation,” Psychological Methods, 19, 459–481.
   PubMed Web of Science ®Google Scholar
• Polverejan, E., and Dragalin, V. (2020), “Aligning Treatment Policy Estimands and Estimators—A Simulation Study in Alzheimer’s Disease,” Statistics in Biopharmaceutical Research, 12, 142–154. DOI: 10.1080/19466315.2019.1689845.
   Web of Science ®Google Scholar
• Purandare, N., Swarbrick, C., Fischer, A., and Burns, A. (2006), “Cholinesterase Inhibitors for Alzheimer’s Disease: Variations in Clinical Practice in the North–West of England,” International Journal of Geriatric Psychiatry, 21, 961–964. DOI: 10.1002/gps.1591.
   PubMed Web of Science ®Google Scholar
• Rogers, J. A., Polhamus, D., Gillespie, W. R., Ito, K., Romero, K., Qiu, R., Stephenson, D., Gastonguay, M. R., and Corrigan, B. (2012), “Combining Patient-Level and Summary-Level Data for Alzheimer’s Disease Modeling and Simulation: A β Regression Meta-Analysis,” Journal of Pharmacokinetics and Pharmacodynamics, 39, 479–498. DOI: 10.1007/s10928-012-9263-3.
   PubMed Web of Science ®Google Scholar
• Rogers, S., Farlow, M., Doody, R., Mohs, R., and Friedhoff, L. (1998), “A 24-Week, Double-Blind, Placebo-Controlled Trial of Donepezil in Patients with Alzheimer’s Disease. Donepezil Study Group,” Neurology, 50, 136–145. DOI: 10.1212/wnl.50.1.136.
   PubMed Web of Science ®Google Scholar
• Rubin, D. B. (1987), Multiple Imputation for Nonresponse in Surveys, New York: Wiley.
   Google Scholar
• Samtani, M. N., Raghavan, N., Novak, G., Nandy, P., and Narayan, V. A. (2014), “Disease Progression Model for Clinical Dementia Rating-Sum of Boxes in Mild Cognitive Impairment and Alzheimer’s Subjects from the Alzheimer’s Disease Neuroimaging Initiative,” Neuropsychiatric Disease and Treatment, 10, 929–952. DOI: 10.2147/NDT.S62323.
   PubMed Web of Science ®Google Scholar
• Valente, M. J., MacKinnon, D. P., and Mazza, G. L. (2020), “A Viable Alternative When Propensity Scores Fail: Evaluation of Inverse Propensity Weighting and Sequential G-Estimation in a Two-Wave Mediation Model,” Multivariate Behavioral Research, 55, 165–187. DOI: 10.1080/00273171.2019.1614429.
   PubMed Web of Science ®Google Scholar
• Vansteelandt, S. (2009), “Estimating Direct Effects in Cohort and Case–Control Studies,” Epidemiology (Cambridge, Mass.), 20, 851–860. DOI: 10.1097/EDE.0b013e3181b6f4c9.
   PubMed Web of Science ®Google Scholar
• Vansteelandt, S., Carpenter, J., and Kenward, M. G. (2010), “Analysis of Incomplete Data using Inverse Probability Weighting and Doubly Robust Estimators,” Methodology, 6, 37–48. DOI: 10.1027/1614-2241/a000005.
   Web of Science ®Google Scholar
• Watt, A. D., Jenkins, N. L., McColl, G., Collins, S., and Desmond, P. M. (2019), “Ethical Issues in the Treatment of Late-Stage Alzheimer’s Disease,” Journal of Alzheimer’s Disease, 68, 1311–1316. DOI: 10.3233/JAD-180865.
   PubMed Web of Science ®Google Scholar